{
    "medicine_id": "dc05570decc42544a34617481aa7dfacc1e56922",
    "platform_id": "DB06343",
    "metadata": {
        "name": "Tepezza 500 mg 1 Injection powder lyophilized for solution",
        "composition": "500 mg 1 Teprotumumab",
        "clinical_particulars": {
            "therapeutic_indications": "Teprotumumab is indicated for the treatment of thyroid eye disease L11359",
            "contraindications": {
                "disease": "Toxicity information including information regarding overdosage is currently unavailable L11359 Symptoms of teprotumumab overdose are likely to be consistent with its adverse effect profile",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Teprotumumab inhibits the downstream effects of IGF 1R signaling namely tissue inflammation and remodeling which are responsible for the various symptoms of thyroid eye disease L11359 A190138 Teprotumumab may cause disease flares in patients with pre existing inflammatory bowel disease IBD patients experiencing an exacerbation should discontinue therapy with teprotumumab Significant hyperglycemia has been observed in patients receiving treatment with teprotumumab which may require antihyperglycemic medications Based on its mechanism of action it is likely that teprotumumab will cause fetal harm in pregnant woman for this reason females of child bearing age should use effective contraception prior to initiation during therapy and for 6 months following the last dose of teprotumumab L11359",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00255",
                        "description": "Diethylstilbestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00269",
                        "description": "Chlorotrianisene may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00286",
                        "description": "Conjugated estrogens may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00655",
                        "description": "Estrone may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00783",
                        "description": "Estradiol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00890",
                        "description": "Dienestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00977",
                        "description": "Ethinylestradiol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01357",
                        "description": "Mestranol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04573",
                        "description": "Estriol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04574",
                        "description": "Estrone sulfate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04575",
                        "description": "Quinestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB07931",
                        "description": "Hexestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09070",
                        "description": "Tibolone may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09317",
                        "description": "Synthetic Conjugated Estrogens A may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09318",
                        "description": "Synthetic Conjugated Estrogens B may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09369",
                        "description": "Polyestradiol phosphate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09381",
                        "description": "Esterified estrogens may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11478",
                        "description": "Zeranol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11674",
                        "description": "Equol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12487",
                        "description": "Promestriene may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13143",
                        "description": "Methallenestril may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13386",
                        "description": "Epimestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13418",
                        "description": "Moxestrol may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13952",
                        "description": "Estradiol acetate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13953",
                        "description": "Estradiol benzoate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13954",
                        "description": "Estradiol cypionate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13956",
                        "description": "Estradiol valerate may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB15334",
                        "description": "Biochanin A may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB15335",
                        "description": "Formononetin may increase the thrombogenic activities of Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00030",
                        "description": "The therapeutic efficacy of Insulin human can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00046",
                        "description": "The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00047",
                        "description": "The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00071",
                        "description": "The therapeutic efficacy of Insulin pork can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00197",
                        "description": "The therapeutic efficacy of Troglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00222",
                        "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00263",
                        "description": "The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00280",
                        "description": "The therapeutic efficacy of Disopyramide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00284",
                        "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00359",
                        "description": "The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00412",
                        "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00414",
                        "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The therapeutic efficacy of Quinine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00491",
                        "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00672",
                        "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00731",
                        "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The therapeutic efficacy of Pentamidine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The therapeutic efficacy of Mifepristone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00839",
                        "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00912",
                        "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00914",
                        "description": "The therapeutic efficacy of Phenformin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01016",
                        "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01067",
                        "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01120",
                        "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01124",
                        "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01132",
                        "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01200",
                        "description": "The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01251",
                        "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01252",
                        "description": "The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01261",
                        "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The therapeutic efficacy of Sunitinib can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01276",
                        "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01277",
                        "description": "The therapeutic efficacy of Mecasermin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01278",
                        "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01289",
                        "description": "The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01306",
                        "description": "The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01307",
                        "description": "The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01309",
                        "description": "The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01382",
                        "description": "The therapeutic efficacy of Glymidine can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01700",
                        "description": "The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04830",
                        "description": "The therapeutic efficacy of Buformin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04876",
                        "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04878",
                        "description": "The therapeutic efficacy of Voglibose can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05115",
                        "description": "The therapeutic efficacy of NN344 can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05819",
                        "description": "The therapeutic efficacy of NBI 6024 can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06011",
                        "description": "The therapeutic efficacy of AMG 222 can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06127",
                        "description": "The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06203",
                        "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06292",
                        "description": "The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06335",
                        "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06655",
                        "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB08382",
                        "description": "The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB08882",
                        "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB08907",
                        "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB08962",
                        "description": "The therapeutic efficacy of Glibornuride can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09022",
                        "description": "The therapeutic efficacy of Benfluorex can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09038",
                        "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09043",
                        "description": "The therapeutic efficacy of Albiglutide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09198",
                        "description": "The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09199",
                        "description": "The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09200",
                        "description": "The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09201",
                        "description": "The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09265",
                        "description": "The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09456",
                        "description": "The therapeutic efficacy of Insulin beef can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB09564",
                        "description": "The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11567",
                        "description": "The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11568",
                        "description": "The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11698",
                        "description": "The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11723",
                        "description": "The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11780",
                        "description": "The therapeutic efficacy of Allicin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11824",
                        "description": "The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11827",
                        "description": "The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11898",
                        "description": "The therapeutic efficacy of 2 4 thiazolidinedione can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11950",
                        "description": "The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB11992",
                        "description": "The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12268",
                        "description": "The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12412",
                        "description": "The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12417",
                        "description": "The therapeutic efficacy of Anagliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12625",
                        "description": "The therapeutic efficacy of Evogliptin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12713",
                        "description": "The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12781",
                        "description": "The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB12935",
                        "description": "The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13406",
                        "description": "The therapeutic efficacy of Carbutamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13446",
                        "description": "The therapeutic efficacy of Guar gum can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13675",
                        "description": "The therapeutic efficacy of Metahexamide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB13928",
                        "description": "The therapeutic efficacy of Semaglutide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB14027",
                        "description": "The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB14035",
                        "description": "The therapeutic efficacy of Englitazone can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB15171",
                        "description": "The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB15217",
                        "description": "The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00002",
                        "description": "The risk or severity of adverse effects can be increased when Cetuximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00028",
                        "description": "The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00043",
                        "description": "The risk or severity of adverse effects can be increased when Omalizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00051",
                        "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00054",
                        "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00056",
                        "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00057",
                        "description": "The risk or severity of adverse effects can be increased when Indium In 111 satumomab pendetide is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00073",
                        "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00074",
                        "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00075",
                        "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00076",
                        "description": "The risk or severity of adverse effects can be increased when Digoxin Immune Fab Ovine is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00078",
                        "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00081",
                        "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00087",
                        "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00089",
                        "description": "The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00095",
                        "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00098",
                        "description": "The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin rabbit is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00108",
                        "description": "The risk or severity of adverse effects can be increased when Natalizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00110",
                        "description": "The risk or severity of adverse effects can be increased when Palivizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00111",
                        "description": "The risk or severity of adverse effects can be increased when Daclizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00113",
                        "description": "The risk or severity of adverse effects can be increased when Technetium Tc 99m arcitumomab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01257",
                        "description": "The risk or severity of adverse effects can be increased when Eculizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01269",
                        "description": "The risk or severity of adverse effects can be increased when Panitumumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of adverse effects can be increased when Ranibizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04901",
                        "description": "The risk or severity of adverse effects can be increased when Galiximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04949",
                        "description": "The risk or severity of adverse effects can be increased when Pexelizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04956",
                        "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04958",
                        "description": "The risk or severity of adverse effects can be increased when Epratuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04962",
                        "description": "The risk or severity of adverse effects can be increased when Bectumomab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04964",
                        "description": "The risk or severity of adverse effects can be increased when Oregovomab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB04988",
                        "description": "The risk or severity of adverse effects can be increased when IGN311 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05006",
                        "description": "The risk or severity of adverse effects can be increased when Adecatumumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05097",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05101",
                        "description": "The risk or severity of adverse effects can be increased when Matuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05111",
                        "description": "The risk or severity of adverse effects can be increased when Fontolizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05136",
                        "description": "The risk or severity of adverse effects can be increased when Bavituximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05139",
                        "description": "The risk or severity of adverse effects can be increased when CR002 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05209",
                        "description": "The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05304",
                        "description": "The risk or severity of adverse effects can be increased when Girentuximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05336",
                        "description": "The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05405",
                        "description": "The risk or severity of adverse effects can be increased when XTL 001 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05437",
                        "description": "The risk or severity of adverse effects can be increased when NAV 1800 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05459",
                        "description": "The risk or severity of adverse effects can be increased when Briakinumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05496",
                        "description": "The risk or severity of adverse effects can be increased when Otelixizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05545",
                        "description": "The risk or severity of adverse effects can be increased when AMG 108 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05550",
                        "description": "The risk or severity of adverse effects can be increased when Iratumumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05555",
                        "description": "The risk or severity of adverse effects can be increased when Enokizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05578",
                        "description": "The risk or severity of adverse effects can be increased when Ramucirumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05595",
                        "description": "The risk or severity of adverse effects can be increased when Farletuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05656",
                        "description": "The risk or severity of adverse effects can be increased when Veltuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05679",
                        "description": "The risk or severity of adverse effects can be increased when Ustekinumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05793",
                        "description": "The risk or severity of adverse effects can be increased when PRO 542 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05797",
                        "description": "The risk or severity of adverse effects can be increased when TNX 901 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05889",
                        "description": "The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05892",
                        "description": "The risk or severity of adverse effects can be increased when RI 624 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05915",
                        "description": "The risk or severity of adverse effects can be increased when MYO 029 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05916",
                        "description": "The risk or severity of adverse effects can be increased when CT 011 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05941",
                        "description": "The risk or severity of adverse effects can be increased when Leronlimab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB05996",
                        "description": "The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06043",
                        "description": "The risk or severity of adverse effects can be increased when Olaratumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06049",
                        "description": "The risk or severity of adverse effects can be increased when IPH 2101 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06050",
                        "description": "The risk or severity of adverse effects can be increased when TB 402 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06081",
                        "description": "The risk or severity of adverse effects can be increased when Caplacizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06101",
                        "description": "The risk or severity of adverse effects can be increased when IMC 1C11 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06116",
                        "description": "The risk or severity of adverse effects can be increased when Eldelumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06162",
                        "description": "The risk or severity of adverse effects can be increased when Lumiliximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06168",
                        "description": "The risk or severity of adverse effects can be increased when Canakinumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06186",
                        "description": "The risk or severity of adverse effects can be increased when Ipilimumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06192",
                        "description": "The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06241",
                        "description": "The risk or severity of adverse effects can be increased when Clenoliximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06273",
                        "description": "The risk or severity of adverse effects can be increased when Tocilizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06304",
                        "description": "The risk or severity of adverse effects can be increased when BIIB015 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06305",
                        "description": "The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06310",
                        "description": "The risk or severity of adverse effects can be increased when Motavizumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06317",
                        "description": "The risk or severity of adverse effects can be increased when Elotuzumab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06318",
                        "description": "The risk or severity of adverse effects can be increased when AVE9633 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06322",
                        "description": "The risk or severity of adverse effects can be increased when Carotuximab is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06324",
                        "description": "The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06342",
                        "description": "The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB06360",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lucatumumab"
                    },
                    {
                        "drugbank-id": "DB06366",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pertuzumab"
                    },
                    {
                        "drugbank-id": "DB06371",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Siplizumab"
                    },
                    {
                        "drugbank-id": "DB06467",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Apolizumab"
                    },
                    {
                        "drugbank-id": "DB06474",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sibrotuzumab"
                    },
                    {
                        "drugbank-id": "DB06550",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bivatuzumab"
                    },
                    {
                        "drugbank-id": "DB06557",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lerdelimumab"
                    },
                    {
                        "drugbank-id": "DB06599",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lexatumumab"
                    },
                    {
                        "drugbank-id": "DB06602",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Reslizumab"
                    },
                    {
                        "drugbank-id": "DB06606",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Teplizumab"
                    },
                    {
                        "drugbank-id": "DB06607",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Catumaxomab"
                    },
                    {
                        "drugbank-id": "DB06612",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mepolizumab"
                    },
                    {
                        "drugbank-id": "DB06643",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Denosumab"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Volociximab"
                    },
                    {
                        "drugbank-id": "DB06650",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ofatumumab"
                    },
                    {
                        "drugbank-id": "DB06674",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Golimumab"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brentuximab vedotin"
                    },
                    {
                        "drugbank-id": "DB08879",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Belimumab"
                    },
                    {
                        "drugbank-id": "DB08902",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Raxibacumab"
                    },
                    {
                        "drugbank-id": "DB08904",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Certolizumab pegol"
                    },
                    {
                        "drugbank-id": "DB08935",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Obinutuzumab"
                    },
                    {
                        "drugbank-id": "DB09029",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Secukinumab"
                    },
                    {
                        "drugbank-id": "DB09033",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vedolizumab"
                    },
                    {
                        "drugbank-id": "DB09035",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Nivolumab"
                    },
                    {
                        "drugbank-id": "DB09036",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Siltuximab"
                    },
                    {
                        "drugbank-id": "DB09037",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pembrolizumab"
                    },
                    {
                        "drugbank-id": "DB09052",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Blinatumomab"
                    },
                    {
                        "drugbank-id": "DB09057",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Anthrax immune globulin human"
                    },
                    {
                        "drugbank-id": "DB09077",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dinutuximab"
                    },
                    {
                        "drugbank-id": "DB09105",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Asfotase alfa"
                    },
                    {
                        "drugbank-id": "DB09264",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Idarucizumab"
                    },
                    {
                        "drugbank-id": "DB09302",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Alirocumab"
                    },
                    {
                        "drugbank-id": "DB09303",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Evolocumab"
                    },
                    {
                        "drugbank-id": "DB09312",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09331",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Daratumumab"
                    },
                    {
                        "drugbank-id": "DB09559",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Necitumumab"
                    },
                    {
                        "drugbank-id": "DB11569",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ixekizumab"
                    },
                    {
                        "drugbank-id": "DB11580",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ravulizumab"
                    },
                    {
                        "drugbank-id": "DB11595",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Atezolizumab"
                    },
                    {
                        "drugbank-id": "DB11604",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tetanus Immune Globulin"
                    },
                    {
                        "drugbank-id": "DB11608",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Eftrenonacog alfa"
                    },
                    {
                        "drugbank-id": "DB11621",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Human Varicella Zoster Immune Globulin"
                    },
                    {
                        "drugbank-id": "DB11646",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Conatumumab"
                    },
                    {
                        "drugbank-id": "DB11657",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tabalumab"
                    },
                    {
                        "drugbank-id": "DB11680",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ficlatuzumab"
                    },
                    {
                        "drugbank-id": "DB11685",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Figitumumab"
                    },
                    {
                        "drugbank-id": "DB11714",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Durvalumab"
                    },
                    {
                        "drugbank-id": "DB11715",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bapineuzumab"
                    },
                    {
                        "drugbank-id": "DB11731",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Depatuxizumab mafodotin"
                    },
                    {
                        "drugbank-id": "DB11746",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Onartuzumab"
                    },
                    {
                        "drugbank-id": "DB11756",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Solanezumab"
                    },
                    {
                        "drugbank-id": "DB11767",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sarilumab"
                    },
                    {
                        "drugbank-id": "DB11771",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tremelimumab"
                    },
                    {
                        "drugbank-id": "DB11776",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brodalumab"
                    },
                    {
                        "drugbank-id": "DB11803",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sirukumab"
                    },
                    {
                        "drugbank-id": "DB11826",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lampalizumab"
                    },
                    {
                        "drugbank-id": "DB11834",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Guselkumab"
                    },
                    {
                        "drugbank-id": "DB11840",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dalotuzumab"
                    },
                    {
                        "drugbank-id": "DB11849",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emibetuzumab"
                    },
                    {
                        "drugbank-id": "DB11850",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ublituximab"
                    },
                    {
                        "drugbank-id": "DB11856",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ligelizumab"
                    },
                    {
                        "drugbank-id": "DB11857",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Seribantumab"
                    },
                    {
                        "drugbank-id": "DB11862",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Landogrozumab"
                    },
                    {
                        "drugbank-id": "DB11866",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Romosozumab"
                    },
                    {
                        "drugbank-id": "DB11884",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vadastuximab Talirine"
                    },
                    {
                        "drugbank-id": "DB11914",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lebrikizumab"
                    },
                    {
                        "drugbank-id": "DB11930",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Varlilumab"
                    },
                    {
                        "drugbank-id": "DB11945",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Avelumab"
                    },
                    {
                        "drugbank-id": "DB11959",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Crenezumab"
                    },
                    {
                        "drugbank-id": "DB11972",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Rilotumumab"
                    },
                    {
                        "drugbank-id": "DB11976",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Anifrolumab"
                    },
                    {
                        "drugbank-id": "DB11988",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ocrelizumab"
                    },
                    {
                        "drugbank-id": "DB12023",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Benralizumab"
                    },
                    {
                        "drugbank-id": "DB12034",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Gantenerumab"
                    },
                    {
                        "drugbank-id": "DB12053",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Visilizumab"
                    },
                    {
                        "drugbank-id": "DB12077",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Urelumab"
                    },
                    {
                        "drugbank-id": "DB12089",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lorvotuzumab mertansine"
                    },
                    {
                        "drugbank-id": "DB12090",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Patritumab"
                    },
                    {
                        "drugbank-id": "DB12102",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fulranumab"
                    },
                    {
                        "drugbank-id": "DB12104",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tarextumab"
                    },
                    {
                        "drugbank-id": "DB12118",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sotatercept"
                    },
                    {
                        "drugbank-id": "DB12119",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Gevokizumab"
                    },
                    {
                        "drugbank-id": "DB12142",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Duligotuzumab"
                    },
                    {
                        "drugbank-id": "DB12152",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Simtuzumab"
                    },
                    {
                        "drugbank-id": "DB12157",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fasinumab"
                    },
                    {
                        "drugbank-id": "DB12159",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dupilumab"
                    },
                    {
                        "drugbank-id": "DB12169",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tralokinumab"
                    },
                    {
                        "drugbank-id": "DB12189",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Etrolizumab"
                    },
                    {
                        "drugbank-id": "DB12202",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Zalutumumab"
                    },
                    {
                        "drugbank-id": "DB12205",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ganitumab"
                    },
                    {
                        "drugbank-id": "DB12213",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Etaracizumab"
                    },
                    {
                        "drugbank-id": "DB12240",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Polatuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB12246",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Inclacumab"
                    },
                    {
                        "drugbank-id": "DB12250",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Cixutumumab"
                    },
                    {
                        "drugbank-id": "DB12261",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ascrinvacumab"
                    },
                    {
                        "drugbank-id": "DB12274",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Aducanumab"
                    },
                    {
                        "drugbank-id": "DB12281",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Luspatercept"
                    },
                    {
                        "drugbank-id": "DB12296",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with GS 5745"
                    },
                    {
                        "drugbank-id": "DB12317",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vanucizumab"
                    },
                    {
                        "drugbank-id": "DB12331",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Labetuzumab govitecan"
                    },
                    {
                        "drugbank-id": "DB12335",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tanezumab"
                    },
                    {
                        "drugbank-id": "DB12342",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ensituximab"
                    },
                    {
                        "drugbank-id": "DB12344",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fezakinumab"
                    },
                    {
                        "drugbank-id": "DB12363",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dusigitumab"
                    },
                    {
                        "drugbank-id": "DB12396",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fresolimumab"
                    },
                    {
                        "drugbank-id": "DB12413",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Indusatumab vedotin"
                    },
                    {
                        "drugbank-id": "DB12456",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bococizumab"
                    },
                    {
                        "drugbank-id": "DB12489",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mirvetuximab Soravtansine"
                    },
                    {
                        "drugbank-id": "DB12498",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12520",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Plozalizumab"
                    },
                    {
                        "drugbank-id": "DB12530",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Inebilizumab"
                    },
                    {
                        "drugbank-id": "DB12534",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mavrilimumab"
                    },
                    {
                        "drugbank-id": "DB12560",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Blosozumab"
                    },
                    {
                        "drugbank-id": "DB12584",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bimagrumab"
                    },
                    {
                        "drugbank-id": "DB12589",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dacetuzumab"
                    },
                    {
                        "drugbank-id": "DB12609",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tovetumab"
                    },
                    {
                        "drugbank-id": "DB12683",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lumretuzumab"
                    },
                    {
                        "drugbank-id": "DB12698",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ibalizumab"
                    },
                    {
                        "drugbank-id": "DB12701",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Intetumumab"
                    },
                    {
                        "drugbank-id": "DB12718",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Carlumab"
                    },
                    {
                        "drugbank-id": "DB12734",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Demcizumab"
                    },
                    {
                        "drugbank-id": "DB12773",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sifalimumab"
                    },
                    {
                        "drugbank-id": "DB12775",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Abituzumab"
                    },
                    {
                        "drugbank-id": "DB12797",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ecromeximab"
                    },
                    {
                        "drugbank-id": "DB12807",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Naptumomab Estafenatox"
                    },
                    {
                        "drugbank-id": "DB12815",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Crotedumab"
                    },
                    {
                        "drugbank-id": "DB12820",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Concizumab"
                    },
                    {
                        "drugbank-id": "DB12826",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Depatuxizumab"
                    },
                    {
                        "drugbank-id": "DB12844",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Rontalizumab"
                    },
                    {
                        "drugbank-id": "DB12845",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Amatuximab"
                    },
                    {
                        "drugbank-id": "DB12849",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Clazakizumab"
                    },
                    {
                        "drugbank-id": "DB12891",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ozanezumab"
                    },
                    {
                        "drugbank-id": "DB12893",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sacituzumab govitecan"
                    },
                    {
                        "drugbank-id": "DB12917",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bimekizumab"
                    },
                    {
                        "drugbank-id": "DB12943",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Milatuzumab"
                    },
                    {
                        "drugbank-id": "DB12976",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Robatumumab"
                    },
                    {
                        "drugbank-id": "DB13017",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Rovalpituzumab Tesirine"
                    },
                    {
                        "drugbank-id": "DB13037",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Namilumab"
                    },
                    {
                        "drugbank-id": "DB13045",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Racotumomab"
                    },
                    {
                        "drugbank-id": "DB13073",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tregalizumab"
                    },
                    {
                        "drugbank-id": "DB13127",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Olokizumab"
                    },
                    {
                        "drugbank-id": "DB13140",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bezlotoxumab"
                    },
                    {
                        "drugbank-id": "DB13375",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Edrecolomab"
                    },
                    {
                        "drugbank-id": "DB13535",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Nebacumab"
                    },
                    {
                        "drugbank-id": "DB13886",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Human cytomegalovirus immune globulin"
                    },
                    {
                        "drugbank-id": "DB13923",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emicizumab"
                    },
                    {
                        "drugbank-id": "DB13976",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sulesomab"
                    },
                    {
                        "drugbank-id": "DB13979",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Besilesomab"
                    },
                    {
                        "drugbank-id": "DB14004",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tildrakizumab"
                    },
                    {
                        "drugbank-id": "DB14012",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Burosumab"
                    },
                    {
                        "drugbank-id": "DB14039",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Erenumab"
                    },
                    {
                        "drugbank-id": "DB14040",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Eptinezumab"
                    },
                    {
                        "drugbank-id": "DB14041",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fremanezumab"
                    },
                    {
                        "drugbank-id": "DB14042",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Galcanezumab"
                    },
                    {
                        "drugbank-id": "DB14211",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Fanolesomab"
                    },
                    {
                        "drugbank-id": "DB14580",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lecanemab"
                    },
                    {
                        "drugbank-id": "DB14597",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lanadelumab"
                    },
                    {
                        "drugbank-id": "DB14707",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Cemiplimab"
                    },
                    {
                        "drugbank-id": "DB14724",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emapalumab"
                    },
                    {
                        "drugbank-id": "DB14762",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Risankizumab"
                    },
                    {
                        "drugbank-id": "DB14776",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Camrelizumab"
                    },
                    {
                        "drugbank-id": "DB14778",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Setrusumab"
                    },
                    {
                        "drugbank-id": "DB14784",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Gancotamab"
                    },
                    {
                        "drugbank-id": "DB14809",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Anetumab ravtansine"
                    },
                    {
                        "drugbank-id": "DB14811",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Isatuximab"
                    },
                    {
                        "drugbank-id": "DB14824",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Icrucumab"
                    },
                    {
                        "drugbank-id": "DB14843",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Codrituzumab"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brolucizumab"
                    },
                    {
                        "drugbank-id": "DB14871",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Xentuzumab"
                    },
                    {
                        "drugbank-id": "DB14877",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lintuzumab"
                    },
                    {
                        "drugbank-id": "DB14891",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vobarilizumab"
                    },
                    {
                        "drugbank-id": "DB14897",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Parsatuzumab"
                    },
                    {
                        "drugbank-id": "DB14905",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emactuzumab"
                    },
                    {
                        "drugbank-id": "DB14907",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bevacizumab zirconium Zr 89"
                    },
                    {
                        "drugbank-id": "DB14908",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Refanezumab"
                    },
                    {
                        "drugbank-id": "DB14919",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Rozanolixizumab"
                    },
                    {
                        "drugbank-id": "DB14947",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bermekimab"
                    },
                    {
                        "drugbank-id": "DB14952",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pamrevlumab"
                    },
                    {
                        "drugbank-id": "DB14959",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Opicinumab"
                    },
                    {
                        "drugbank-id": "DB14962",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Trastuzumab deruxtecan"
                    },
                    {
                        "drugbank-id": "DB14967",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Margetuximab"
                    },
                    {
                        "drugbank-id": "DB14988",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dalantercept"
                    },
                    {
                        "drugbank-id": "DB14997",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pateclizumab"
                    },
                    {
                        "drugbank-id": "DB15014",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Gremubamab"
                    },
                    {
                        "drugbank-id": "DB15022",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Apomab"
                    },
                    {
                        "drugbank-id": "DB15044",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tafasitamab"
                    },
                    {
                        "drugbank-id": "DB15045",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ipafricept"
                    },
                    {
                        "drugbank-id": "DB15076",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Abrilumab"
                    },
                    {
                        "drugbank-id": "DB15089",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Frovocimab"
                    },
                    {
                        "drugbank-id": "DB15090",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tezepelumab"
                    },
                    {
                        "drugbank-id": "DB15101",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tigatuzumab"
                    },
                    {
                        "drugbank-id": "DB15104",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Telisotuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15113",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Utomilumab"
                    },
                    {
                        "drugbank-id": "DB15118",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Zolbetuximab"
                    },
                    {
                        "drugbank-id": "DB15135",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ponezumab"
                    },
                    {
                        "drugbank-id": "DB15160",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Asunercept"
                    },
                    {
                        "drugbank-id": "DB15172",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Suvratoxumab"
                    },
                    {
                        "drugbank-id": "DB15225",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mitazalimab"
                    },
                    {
                        "drugbank-id": "DB15252",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Nemolizumab"
                    },
                    {
                        "drugbank-id": "DB15253",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bleselumab"
                    },
                    {
                        "drugbank-id": "DB15277",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Gedivumab"
                    },
                    {
                        "drugbank-id": "DB15336",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Valanafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15349",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Sofituzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15354",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Evinacumab"
                    },
                    {
                        "drugbank-id": "DB15363",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Istiratumab"
                    },
                    {
                        "drugbank-id": "DB15383",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pidilizumab"
                    },
                    {
                        "drugbank-id": "DB15397",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with GMA 161"
                    },
                    {
                        "drugbank-id": "DB15409",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ladiratuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15415",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Tomaralimab"
                    },
                    {
                        "drugbank-id": "DB15428",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Vesencumab"
                    },
                    {
                        "drugbank-id": "DB15432",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pinatuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15441",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lulizumab pegol"
                    },
                    {
                        "drugbank-id": "DB15443",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Lorukafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15453",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Naratuximab emtansine"
                    },
                    {
                        "drugbank-id": "DB15559",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Zenocutuzumab"
                    },
                    {
                        "drugbank-id": "DB15898",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Atoltivimab"
                    },
                    {
                        "drugbank-id": "DB15899",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Maftivimab"
                    },
                    {
                        "drugbank-id": "DB15900",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Odesivimab"
                    },
                    {
                        "drugbank-id": "DB15719",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB00214",
                        "description": "The risk or severity of ototoxicity can be increased when Torasemide is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00695",
                        "description": "The risk or severity of ototoxicity can be increased when Furosemide is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00903",
                        "description": "The risk or severity of ototoxicity can be increased when Etacrynic acid is combined with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00331",
                        "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB15595",
                        "description": "The therapeutic efficacy of Ebola Zaire vaccine live attenuated can be decreased when used in combination with Teprotumumab"
                    },
                    {
                        "drugbank-id": "DB00994",
                        "description": "The risk or severity of ototoxicity can be increased when Teprotumumab is combined with Neomycin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}